- A pharmacist identifies during DUR that a pediatric patient has been prescribed an adult dose of an antibiotic. Which of the following best applies?
Answer: Contact the prescriber to verify the dose is safe for the child's age and weight before dispensing.
An apparent overdose for a pediatric patient identified during DUR requires prescriber verification before dispensing. The pharmacist should withhold dispensing and contact the prescriber. C correctly describes this required action. A is incorrect because the DUR obligation exists precisely to catch prescribing errors; deferring without verification is not appropriate. B is incorrect because unilaterally adjusting the dose without prescriber authorization is outside the pharmacist's scope. D is incorrect because dispensing half without prescriber guidance is both clinically inappropriate and outside the pharmacist's authority.
- Under OBRA '90, which of the following best describes prospective drug utilization review (DUR) as it applies to pharmacists dispensing Medicaid prescriptions?
Answer: Prospective DUR involves reviewing prescriptions and patient history to identify potential drug therapy issues.
OBRA '90 established prospective DUR as a mandatory clinical review that pharmacists must perform before dispensing prescriptions to Medicaid patients -- reviewing the prescription against the patient's medication history to identify drug therapy problems including drug interactions, therapeutic duplications, inappropriate drug or dose, contraindications, and adverse drug reactions. B correctly describes this obligation. A is incorrect because prospective DUR is mandatory, not optional. C is incorrect because it applies to all prescriptions, not only Schedule II controlled substances. D is incorrect because prescriber contact is required only when problems are identified, not before every dispense.
- A state board requires pharmacies to maintain records of all prospective DUR interventions. A pharmacy's audit reveals it has been documenting DUR overrides but not DUR interventions where the prescription was modified or not dispensed. Which of the following best analyzes the compliance concern?
Answer: The pharmacy is non-compliant; DUR records must include all interventions, not just overrides.
Complete DUR recordkeeping must capture all intervention types, not only overrides. Documenting only overrides omits the interventions most likely to reflect genuine drug therapy problem identification. C correctly identifies the compliance deficiency. A is incorrect because overrides, while important, are not the only required DUR record. B is incorrect because the dispensing record does not capture the clinical rationale for modifications or non-dispenses. D is incorrect because interventions resulting in modification or non-dispense are actually the most clinically significant DUR outcomes and must be documented.
- Which of the following best describes the pharmacist's DUR obligation when a newly presented prescription triggers an alert for a potentially life-threatening drug interaction and the prescriber is immediately reachable by phone?
Answer: Contact the prescriber, inform them of the interaction, and await their instructions before dispensing.
A potentially life-threatening drug interaction requires immediate prescriber contact and withholding the prescription pending clinical guidance. Documentation of the entire interaction -- the alert, the prescriber conversation, the prescriber's instructions, and the outcome -- is required. D correctly describes this complete intervention. A is incorrect because counseling alone does not address a potentially life-threatening interaction. B is incorrect because overriding a life-threatening interaction alert without clinical review is a DUR failure. C is incorrect because permanent refusal without prescriber consultation is premature; the prescriber may confirm clinical urgency justifying the prescription.
- A pharmacist performs DUR and identifies a significant drug-disease contraindication -- the patient has documented kidney disease and has been prescribed a medication that is contraindicated in renal failure. Which of the following best describes the appropriate action?
Answer: Contact the prescriber to discuss the contraindication and withhold dispensing until receiving further instructions. Document the intervention.
A drug-disease contraindication identified during DUR requires immediate prescriber contact and withholding the prescription pending clinical review. The pharmacist must document the intervention and, if the prescriber confirms, document the rationale. C correctly describes this process. A is incorrect because assuming the prescriber is aware does not discharge the pharmacist's DUR obligation. B is incorrect because permanent refusal without prescriber consultation is premature; the prescriber may have a clinical justification. D is incorrect because adjusting quantity or dose without prescriber authorization is outside the pharmacist's scope.
- A pharmacist performs DUR on a new prescription for an antidepressant for a patient who is already taking a different antidepressant. The pharmacist believes this may be therapeutic duplication. Which of the following most accurately describes when two antidepressants would NOT constitute therapeutic duplication?
Answer: Two antidepressants from different classes may be combined for treatment-resistant depression.
Intentional combination of two antidepressants -- particularly from different classes -- is a recognized clinical practice for augmentation or treatment-resistant depression. When prescribed intentionally with documented clinical rationale, it is not therapeutic duplication in the clinical DUR sense. B correctly identifies this distinction. A is incorrect because combination antidepressant therapy is a legitimate clinical practice. C is incorrect because same-class combinations raise greater duplication concerns and are less commonly clinically intentional. D is incorrect because DUR principles including therapeutic duplication apply to psychiatric medications.
- A patient presents a prescription for a blood thinner. During prospective DUR, the pharmacist notes the patient is also taking aspirin. The prescriber's office confirms both were intentionally prescribed and the clinical rationale is documented. Which of the following best describes the pharmacist's next obligation?
Answer: Dispense the medication and counsel the patient on potential bleeding risks associated with combination therapy.
Once a DUR concern has been resolved through prescriber verification and documentation, the pharmacist should dispense and counsel the patient on the clinical implications of the combination therapy -- specifically the enhanced bleeding risk and warning signs. A correctly identifies this complete response. B is incorrect because intentional combination therapy with documented clinical rationale does not warrant refusal. C is incorrect because prescriber verification of the combination does not eliminate the pharmacist's independent counseling obligation. D is incorrect because partial fill without a specific clinical indication is not the appropriate response.
- A pharmacist's prospective DUR identifies that a patient's new prescription for amoxicillin is a therapeutic duplication -- the patient already has an active prescription for another penicillin antibiotic for the same infection. Which of the following best describes the appropriate response?
Answer: Contact the prescriber to verify the prescription and document the clarification before dispensing.
Therapeutic duplication identified during DUR requires prescriber contact to clarify intent before dispensing. Dispensing two antibiotics from the same class for the same infection without verification could harm the patient or reflect a prescribing error. B correctly identifies this intervention. A is incorrect because the pharmacist has a DUR obligation to address identified problems, not simply defer to the order. C is incorrect because instructing the patient to stop a prior prescription without prescriber authorization is outside the pharmacist's scope. D is incorrect because substituting to a different antibiotic without prescriber authorization is not appropriate.
- Which of the following drug therapy problems is prospective DUR specifically designed to identify before a prescription is dispensed?
Answer: Drug-drug interactions and contraindications before dispensing.
Prospective DUR is designed to identify clinical drug therapy problems before dispensing: drug-drug interactions, therapeutic duplications, inappropriate drug or dose for the indication, allergy conflicts, contraindications, and potential adverse drug reactions. A correctly identifies these clinical targets. B is incorrect because insurance coverage determination is an administrative function, not a clinical DUR component. C is incorrect because the pharmacist evaluates appropriateness of the prescription, not whether the pharmacist concurs with the diagnosis. D is incorrect because affordability assessment is not a DUR function.
- Under OBRA '90, what is the purpose of pharmacies maintaining a medication history for each patient?
Answer: To enable effective prospective DUR by evaluating new prescriptions with current medications.
Patient medication history is maintained to enable effective prospective DUR. Without a medication history, the pharmacist cannot identify interactions, duplications, or contraindications across the patient's complete medication regimen. D correctly identifies this clinical purpose. A is incorrect because insurance compliance is not the purpose of patient medication history under OBRA '90. B is incorrect because pharmacists do not use diagnostic codes to facilitate prescribing. C is incorrect because DEA controlled substance profiling is a distinct function from OBRA '90 medication history requirements.
- A DUR system flags a drug interaction between a proton pump inhibitor and clopidogrel. The interaction is clinically controversial -- some guidelines suggest clinical significance while others find no meaningful effect. How should the pharmacist proceed?
Answer: Consult the prescriber, document assessment, and counsel the patient on risks.
Clinically controversial interactions require pharmacist judgment informed by current evidence and clinical context. Consulting the prescriber -- particularly for high-risk patients -- and documenting the assessment are appropriate. D correctly describes this evidence-based, patient-centered approach. A is incorrect because overriding without any clinical evaluation fails the DUR obligation. B is incorrect because controversial evidence does not mandate prescription cancellation. C is incorrect because counseling remains important even for uncertain interactions, especially for high-risk patients.
- A pharmacist's DUR system generates an alert for every prescription in a high-volume pharmacy. The pharmacist develops a routine of clicking through alerts without reviewing them to maintain workflow speed. Which of the following best analyzes this practice?
Answer: This practice violates DUR obligations by bypassing required clinical review, risking patient safety through failure to assess potential drug therapy issues.
DUR requires genuine clinical review -- not mechanical processing. A pattern of reflexively clicking through all alerts without clinical evaluation defeats the purpose of DUR and creates patient safety risk. B correctly identifies this as a DUR compliance violation. A is incorrect because DUR alerts are meant to be clinically evaluated, not presumptively overridden; the system generates alerts to prompt review, not to be systematically bypassed. C is incorrect because selective alert review limited to the highest-severity alerts still fails to assess lower-severity alerts that may be clinically significant; all alerts require at least a brief clinical assessment before override. D is incorrect because workflow volume demands do not create exceptions to DUR obligations; high volume requires efficient review processes, not abandonment of review.
- During DUR for a new opioid prescription, the pharmacist notes the patient has a documented allergy to the opioid class listed in her profile. The patient insists she no longer has the allergy and it was a misidentification years ago. Which of the following best applies?
Answer: Consult the prescriber to verify allergy status before dispensing or updating the patient's profile.
A documented drug allergy is a DUR concern that requires prescriber involvement before dispensing. Patients cannot unilaterally remove their own allergy flags from pharmacy records, and the pharmacist should not override an allergy alert based solely on the patient's verbal statement. C correctly identifies the required process: contact the prescriber, communicate the patient's claim, and withhold dispensing until the prescriber formally reviews and addresses the allergy documentation. A is incorrect because patients cannot override clinical allergy documentation without prescriber involvement; the allergy flag is a clinical record, not a patient preference setting. B is incorrect because allergy entries can be corrected with proper clinical authorization if they were genuinely erroneous; a blanket prohibition on ever dispensing is too absolute. D is incorrect because the pharmacist's independent clinical assessment is insufficient to override a documented allergy; prescriber authorization is required before the profile can be updated and the prescription dispensed.
- A pharmacist performs DUR before dispensing a refill of metformin and notices a new laboratory result in the patient's profile showing the patient's eGFR has dropped to a level at which metformin use is contraindicated. The prescriber has not yet been notified. Which of the following best applies?
Answer: Withhold the refill and immediately contact the prescriber to report the new lab finding and the contraindication; document the intervention and await prescriber guidance before dispensing.
A new laboratory finding indicating a contraindication to the patient's current medication requires immediate prescriber notification and withholding the refill pending clinical review. B correctly identifies this urgent intervention. A is incorrect because deferring to the next appointment when a known contraindication exists is a patient safety failure. C is incorrect because enhanced counseling does not address the underlying safety concern when a contraindication has emerged. D is incorrect because dispensing any quantity of a contraindicated drug without prescriber guidance creates liability and patient risk.
- Retrospective DUR differs from prospective DUR in which of the following key ways?
Answer: Retrospective DUR analyzes past prescription data; prospective DUR reviews prescriptions before dispensing.
Retrospective DUR is a population-level review of drug use patterns conducted after dispensing has occurred, aimed at identifying systemic issues across a patient population. Prospective DUR is the real-time, individual patient-level clinical review performed before each dispense. D correctly describes this distinction. A is incorrect because the timing is reversed. B is incorrect because neither type is limited to controlled substances. C is incorrect because both prospective and retrospective DUR have regulatory bases; the distinction is temporal and individual vs. population level.
- A high-volume retail pharmacy implements a policy requiring pharmacists to complete DUR on all new prescriptions within 60 seconds to maintain patient flow. Which of the following best analyzes this policy?
Answer: The policy may compromise DUR quality, as time limits can hinder thorough clinical reviews.
Imposing rigid time limits on DUR creates the risk of inadequate clinical review, particularly for complex patients. DUR requirements mandate genuinely meaningful clinical assessment, which cannot always be completed in a fixed time. C correctly identifies the compliance concern. A is incorrect because efficiency goals cannot override clinical thoroughness requirements. B is incorrect because 60 seconds is clearly insufficient for complex multi-drug patients requiring thorough DUR. D is incorrect because state DUR laws do not specify maximum review times for high-volume settings.
- How must a pharmacist document a DUR intervention when a drug interaction is identified and the prescriber is contacted?
Answer: Document the DUR problem, prescriber contact details, conversation summary, prescriber's response, and prescription outcome per state regulations.
OBRA '90 established the DUR framework requiring documentation of interventions, and state laws and pharmacy practice standards flesh out the specific documentation elements. A complete DUR intervention record should capture the problem identified, when the intervention occurred, who was contacted, what was discussed, the prescriber's response, and the dispensing outcome; some states and institutional policies may specify additional elements. B correctly identifies this best-practice documentation framework. A is incorrect because verbal prescriber confirmation is important to document even when the prescription proceeds; the record must reflect the intervention occurred. C is incorrect because patient name and drug alone are far too minimal to constitute adequate intervention documentation. D is incorrect because documentation is required regardless of dispensing outcome; completed dispenses following DUR interventions must also be documented.
- A pharmacy's DUR program identifies that a patient has been filling the same medication at multiple pharmacies -- a pattern consistent with potential drug seeking. Which of the following best describes how DUR intersects with this situation?
Answer: DUR alerts the pharmacist to review overutilization patterns and consult the PDMP before dispensing.
DUR encompasses overutilization as well as clinical drug therapy problems. A pattern of multiple pharmacy fills may trigger an overutilization DUR alert, requiring the pharmacist to investigate, consult the PDMP, and apply corresponding responsibility analysis before dispensing. D correctly identifies this DUR dimension. A is incorrect because overutilization is explicitly a DUR category alongside clinical drug therapy problems. B is incorrect because PDMP consultation and corresponding responsibility are directly relevant to this DUR scenario, not exclusively DEA matters. C is incorrect because DUR findings trigger clinical and professional investigation obligations; immediate mandatory law enforcement reporting is not the required DUR response to a potential overutilization pattern.
- A pharmacist performs prospective DUR and identifies a potential drug-drug interaction between a newly prescribed medication and a medication the patient already takes. Which of the following best describes the required action?
Answer: Contact the prescriber to discuss the interaction and determine if dispensing is appropriate.
When a significant drug-drug interaction is identified during DUR, the pharmacist must contact the prescriber before dispensing to discuss the interaction and determine the appropriate clinical course of action. The intervention must be documented. C correctly describes this workflow. A is incorrect because noting without acting fails the DUR obligation when a significant interaction exists. B is incorrect because not all identified interactions require permanent refusal; clinical severity determines the response. D is incorrect because dispensing without prescriber consultation when a significant interaction exists shifts responsibility to the patient and bypasses the required clinical intervention.
- A pharmacist reviewing a prescription for an elderly patient identifies that the prescribed medication is on the Beers Criteria list of potentially inappropriate medications for older adults. Which of the following best describes the pharmacist's DUR obligation?
Answer: Review the patient's profile, discuss concerns with prescriber, suggest alternatives, document actions, and provide enhanced counseling if dispensing.
Beers Criteria flags require clinical DUR judgment applied to the individual patient. The pharmacist should contact the prescriber to discuss the concern and potential alternatives, document the intervention, and if the prescriber confirms after discussion, dispense with counseling on monitoring. A correctly describes this individualized approach. B is incorrect because Beers listings identify potential concerns, not categorical prohibitions. C is incorrect because dismissing Beers Criteria flags without any clinical review fails the DUR obligation. D is incorrect because referring to a geriatrician without first addressing the concern with the prescriber bypasses the required DUR intervention.
